Kereos Named Among Top 15 Biotech Companies of 2004 by FierceBiotech

Jul 28, 2004, 01:00 ET from Kereos

    ST. LOUIS, July 28 /PRNewswire/ -- Kereos, a biotechnology company
 developing targeted therapeutics and molecular imaging agents for the
 treatment and detection of cancer and cardiovascular disease, announced today
 that it has been selected as one of the "Fierce 15" for 2004 by FierceBiotech,
 an internationally-recognized publication for the biotech industry.  Kereos
 was chosen as one of the top emerging biotechnology companies from more than
 500 privately held firms for the company's vision, management expertise, and
 overall potential to change the way disease is treated.
     "Kereos' development of nanotechnology-based targeted therapeutics and
 imaging agents could result in the earlier detection and more targeted
 treatment of two leading killers of Americans -- cardiovascular disease and
 cancer," said John Carroll, editor of FierceBiotech.  "The Fierce 15
 celebrates the spirit of innovation and aggressive development of new
 products, and we are pleased to honor those biotechnology companies with great
 potential to change the landscape of biotechnology."
     "We believe that our cancer products will enable physicians to find tumors
 earlier and treat them more effectively, while our lead cardiovascular
 products should be the first to find and treat the unstable plaque underlying
 most heart attacks," said Robert "Al" Beardsley, Ph.D., CEO of Kereos.
 "Kereos is honored to be chosen from among so many outstanding companies in
 our industry, and to be recognized for that vision and for the experienced
 team of professionals dedicated to realizing it."
     The Fierce 15 roster of winners is available in today's issue of
 FierceBiotech and on the FierceBiotech Web site at
     Kereos develops products designed to provide more effective treatment and
 detection of cancer and cardiovascular disease, the first of which is expected
 to enter clinical trials in 2005.  In addition to advancing its pipeline of
 therapeutic and imaging candidates independently, Kereos is committed to
 partnering with leading pharmaceutical and imaging companies.  To date, it has
 formed collaborations with Bristol-Myers Squibb Medical Imaging for the
 development and commercialization of cardiovascular disease magnetic resonance
 imaging (MRI) agents and with Philips Medical Systems for the development of
 molecular imaging systems.  For more information, visit Kereos' website at
     FierceBiotech is an internationally recognized email newsletter for the
 biotech industry.  Every business day, more than 31,000 executives in over
 100 countries rely on FierceBiotech for a quick, authoritative briefing on the
 day's top stories.  It is published by FierceMarkets, Inc. a business
 publishing company based in Washington D.C.